Introduction {#sec1-1}
============

Dysmenorrhea is the most common gynecological problem faced by women during their adolescence. It causes significant discomfort and anxiety for the woman as well as her family. A systematic review of studies from developing countries revealed that about 25%--50% of adult women and about 75% of adolescents experience pain during menstruation, with 5%--20% reporting severe dysmenorrhea or pain that is severe enough to prevent them from carrying out their day-to-day activities.\[[@ref1]\] The word *Kashtartava* itself gives an idea of the difficulty experienced during menstruation.\[[@ref2]\] *Kashtartava* can be taken to be the same as the 'dysmenorrhea' of modern medicine. For the present study we only considered primary dysmenorrhea as *Kashtartava* so that we would have clear-cut inclusion and exclusion criteria when selecting patients and to facilitate statistical analysis of data. Primary dysmenorrhea is a condition which causes painful menstruation without any demonstrable pelvic pathology.\[[@ref3]\] In addition to menstrual pain, many woman experience associated symptoms such as headache, constipation, nausea, vomiting, fatigue, and leg pains.

The etiology of uterine pain in primary dysmenorrhea is still not established. But several risk factors have been identified, such as young age, early menarche, positive family history, nulliparity, stress/depression, and smoking. There are many theories regarding the pathophysiology of the condition,\[[@ref4]\] with the prostaglandin theory being the one that is most generally accepted.

The treatment usually advocated in modern medicine, i.e., analgesics, antispasmodics, and/or oral contraceptive pills,\[[@ref5]\] does not provide a long-lasting solution and, besides, may lead to serious adverse effects. As yet there is no treatment regimen that can relieve the entire symptom complex of primary dysmenorrhea. Hence, there is a need to find a safe and long-lasting treatment for the condition. *Kashtartava*, especially when it manifests as primary dysmenorrhea, is a *Vata*-dominant condition. The two drugs that we selected for this study are good *Vatashamaka* drugs according to the classic texts. *Dashamoola* oil has been advocated for the treatment of *Udavarta Yonivyapada*,\[[@ref6]\] which is one of the main disease conditions included under the term *Kashtartava* (primary dysmenorrhea). *Tila Taila* (sesame oil) is the best drug for the treatment of *Vataja* condition\[[@ref7]\] and also has properties of *Yoni Shula Prashamana* and *Garbhashaya Vishodhana*.\[[@ref8][@ref9]\]

Aims and Objectives {#sec1-2}
===================

The aims of the study were to find out the efficacy of *Matra Basti* on the symptom complex of *Kashtartava* (primary dysmenorrhea) and to compare the efficacies of the two selected drugs in relieving *Kashtartava*

Materials and Methods {#sec1-3}
=====================

Preparation of drugs {#sec2-1}
--------------------

The ten ingredients of dried *Dashamoola* were collected from the pharmacy of Gujarat Ayurved University, Jamnagar.Microscopic examination of the powder showed the presence of root as well as stem bark of the plants. Equal amounts of the ten ingredients were taken and made into *Yavakuta* (crude powder) form. This was soaked in water overnight and, on the next day, *Kwatha* was prepared. This *Kwatha* along with *Kalka* of *Dashamoola* was added in *Tila Taila*, and *Sneha* was prepared as per the standard protocol.\[[@ref10]\] The *Tila Taila* used for the study was purchased from an oil mill at Jamnagar. An analytical study of both the oils was carried out with the help of the Pharmaceutical Chemistry laboratory, IPGT and RA, before using them in the clinical study.

Selection of patients {#sec2-2}
---------------------

The subjects for the study were selected from among the outpatients and inpatients of the department of Striroga and Prasooti Tantra, IPGT and RA, Gujarat Ayurved University, Jamnagar. Patients in the age-group of 15--25 years, with the chief complaint of painful menses for at least three cycles, with scanty or normal amount of bleeding. Patients below 15 years and above 25 years, patients with chronic illness, patients using an intrauterine contraceptive device, and patients with menorrhagia or any uterine pathology (fibroid, adenomyosis, endometriosis, etc.) were excluded from the study.

Investigations {#sec2-3}
--------------

Routine hematological and urinary examinations were done before and after treatment. Sonography to rule out uterine and adnexal pathology was done as per need.

Follow-up {#sec2-4}
---------

After completion of the treatment course the patients were requested to report for follow-up every 7 days for 2 months.

Method of administration of *Matra Basti* {#sec2-5}
-----------------------------------------

The patient was advised to have a light meal on the day of treatment. Before administration of *Basti, Abhyanaga* (massage) with *Tila Taila* was done of the back and lower abdomen. Thereafter, *Nadi Sweda* (sudation) was performed. After this *Purvakarma*, the patient was asked to lie down in the left lateral position with the left lower extremity extended and the right lower extremity flexed at the knees and hips. Then 60 ml of lukewarm oil was loaded in an enema syringe. A rubber catheter oleated with oil was attached to the enema syringe. After any air in the enema syringe had been expelled, the rubber catheter was passed through the anus of the patient up to a length of 4 inches and the drug was administered. The patient was asked to take deep breaths during the passage of the catheter and the administration of the drug. The entire oil in the syringe was not administered in order to avoid entrance of *Vayu* into the *Pakvashaya* as it may produce pain. After the administration of *Basti*, the patient was advised assume the supine position. While in this position, the patient\'s buttocks were gently tapped and the legs were raised for a few minutes so as to raise the waist. These measures were intended to prevent the administered fluid from flowing out too soon. After a short time the patient was allowed to get up from the [Table 1](#T1){ref-type="table"}, and she was then advised to rest in bed for at least ½ an hour.
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Assessment {#sec2-6}
----------

Scoring for different parameters was done as follows {#sec2-7}
----------------------------------------------------

### Pain (dysmenorrhea) {#sec3-1}

Severity of pain (multidimensional scoring pattern)0Menstruation is not painful and daily activity is unaffected.1Menstruation is painful but daily activity is not affected. No analgesic required.2Menstruation is painful and daily activity is affected. Analgesic drug is needed.3Menstruation is so painful that patient is unable to do even the routine work and has to miss class/office during menses. Has to take analgesic, but without much relief.Duration0No pain during menstruation1Pain persists for less than 12 h2Pain persists for 12-24 h3Pain persists for more than 24 h

### Associated symptoms {#sec3-2}

*Artava Pramana* (assessment by number of pads used)06--7 pads/cycle14--5 pads/cycle22--3 pads/cycle3Spotting or 1 pad/cycleRajasrava Avadhi0Duration of menses 4--7 days1Duration of menses 3 days2Duration of menses 2 days3Duration of menses 1 dayPraseka (nausea)0No *Praseka* (nausea)12--3 times/day24--5 times/day3\>5 times/day*Chhardi* (vomiting)0No *Chhardi*1Occasionally21--2 times/day3More than 2 times/day*Vibandha* (constipation)0No *Vibandha*1Frequency of stool once in a day, but hard stools passed2Frequency of stool alternate days and patient has difficulty in defecation3Patient cannot pass stool without the help of a purgative even after 3--4 daysAtisara (diarrhea)0No *Atisara*1Occasionally22--3 times/day and *Drava Mala Pravritti*3More than 3 times/day and *Drava Mala PravrittiShrama* (fatigue)0No *Shrama*1Fatigue induced by having to even single extra work in addition to the daily routine2Fatigued by the normal daily routine3Severe fatigue even without work*Aruchi* (loss of appetite)0Takes a full diet and also has proper appetite at the next meal time1Presence of moderate appetite and promote appearance of appetite in next meal time2Presence of low appetite but delayed appearance of appetite in next meal time3Persisting low appetite or frequent loss of appetite; unable to consume even the minimum required diet*Shirashula* (headache)0No headache1Headache once during each menstruation; persists for less than 6 h2Frequent headache 2--3 times per menstruation; daily activity not affected3Persistent headache throughout the menstruation; daily activity affected*Vankshana Shula* (tenesmus of the bladder), *Kati Shula*, and *Janu Shula*0No pain1Presence of all three for less than 1 h / any two features for less than 6 h / any one feature for less than 12 h2Presence of all three for 1--2 h / any two features for 6--12 h / any one feature for more than 12 h3Presence of all three for more than 2 h / any two features for 12--24 h / any one feature for more than 24 h*Swedadikya* (excessive sweating)0No sweating1Occurs only on working in a hot environment or doing hard work2More in the day time / associated with or following hot flushes only3Excessive sweating to the extent that the patient needs to change her clothes or have a bath*Tamodarshana* (faints)0No faints1Occasionally, once per menstruation2Faints once during each menstruation3More than once during each menstruation

Criteria for the assessment of overall effect of the therapies {#sec2-8}
--------------------------------------------------------------

For assessing the total effect of the therapy we took into consideration the overall improvement in signs and symptoms. The patients were categorized as follows:

Complete remission: 76%--100% relief in the signs and symptomsMarked improvement: 51%--75% relief in the signs and symptoms Improved: 26%--50% relief in the signs and symptoms.Unchanged: Below 25% relief in the signs and symptoms

Observations {#sec1-4}
============

A total 40 patients registered for the study and out them 35 completed the full course of treatment: 18 in group A and 17 in group B. Five patients discontinued treatment. The general observations are shown in [figure 1](#F1){ref-type="fig"}.
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Results and Discussion {#sec1-5}
======================

For the present study, only primary dysmenorrhea was considered under *Kashtartava*. We did this in order to exclude the pathological cases; however, no disease can be primary according to Ayurvedic principles as every disease has a certain pathology underlying it. Although it is not absolutely correct to say a disease is 'primary' in Ayurvedic terminology, we overlooked this so that we would have clear-cut inclusion and exclusion criteria and also to facilitate statistical analysis of data.

For the purposes of this study, therefore, we made an effort to classify all disorders with any type of pain or discomfort related to menstruation as either primary or secondary. All menstrual disorders in which pain or discomfort was the most prominent feature were categorized as primary dysmenorrhea; those in which there were local features such as inflammation or systemic features such as fever were considered as secondary dysmenorrhea. There are several conditions, including *Vatala, Vataja Artavadushti, Udavarta, Suchimukhi, and Artavakshaya*, in which there is pain associated with menstruation along with backache, pain in groins, stiffness, etc. but no abnormality of menstruation other than perhaps a decrease in the amount of flow or the duration. This picture suggests that these conditions are a form of primary dysmenorrhea, without any pelvic pathology. Other diseases such as *Sannipataki, Paripluta, Asrugdhara, and Kshina Artava Dushti* show specific menstrual irregularities, i.e., heavy bleeding, intermenstrual bleeding, yellow or green colored discharge, yellow or green discoloration, or abnormal odor, etc., along with dysmenorrhea. Some are also associated with fever. Thus, these conditions can be classified as secondary dysmenorrhea, where there is involvement of *Dosha* other than *Vata*.

The risk factors for *Kashtartava* that we identified in this study were similar to those mentioned for dysmenorrhea \[[Figure 2](#F2){ref-type="fig"}\]. Early onset of menarche and early age at menarche, which are mentioned as risk factors for dysmenorrhea,\[[@ref11]\] were found in 68.57% and 77.14% of patients, respectively. The theory postulated to explain this finding is that the pituitary and other endocrine gland do not attain their maturity till the age of 20 years. This can lead to hormonal imbalance and, thus, dysmenorrhea. A positive family history of dysmenorrhea was found in 77.24% of patients, which supports the concept of '*Kulaja*' in Ayurveda. This is considered as a risk factor in modern science also. Nulliparity, which is considered a risk factor for dysmenorrhea was found in 85.71% of patients. Vaginal delivery removes any stenosis of the cervical canal and thus facilitates the flow of menstrual blood. History of smoking was not found in any patient. This is not surprising as smoking is uncommon among Indian women.

![Risk factors of patients](Ayu-31-305-g003){#F2}

Nidana {#sec2-9}
------

Almost all the patients were consuming the causative factors of Vata vitiation \[[Figure 3](#F3){ref-type="fig"}\]. *Vishamashana* (improper dietary habits) was found in 54.28% patients. It is a very important factor for aggravation of *Vata*. Other *Vata*-vitiating dietetic factors were also found in some patients, such as intake of *Laghu* and *Ruksha Guna* (light and ununctuous) diet in 22.85% and intake of *Shita* (cold) diets in 17.14%. *Katu Rasa* dominance was found in 34.28% of patients and this is also known to vitiate *Vata*. Thus, *Vata Vardhaka Nidanas* are important factors for causing *Kashtartava*. With regard to the *Manasika Nidanas* (psychological factors), *Chinta* (worry), *Shoka* (grief), and *Bhaya* (fear) were found in 54.28%, 40%, and 31.42% of patients, respectively. These are *Vatavardhaka* factors and are becoming commoner in young girls because of changing lifestyles. This is an era of competition and young girls have to face more challenges today than in the past.

![Nidana related to *Kashtartava*](Ayu-31-305-g004){#F3}

Associated symptoms {#sec2-10}
-------------------

Though hypomenorrhea and oligomenorrhea are not mentioned as the associated symptoms of dysmenorrhea in modern texts, it is described in the Ayurvedic classics as *Yathochitakala Adarshanam* (oligomenorrhea) and *Alpartava* (hypomenorrhea). In our study, 22.85% of patients had *Alpartava* and 37.14% had oligomenorrhea \[[Figure 4](#F4){ref-type="fig"}\]. Thus, the data regarding this observation are suggestive of the Ayurvedic approach of relation of *Alpartava* with *Kashtartava*. This relationship can be very well explained on the basis of vitiation of *Vata*, as both *Alpartava* and *Kashtartava* are the outcome of *Vata Vriddhi. Aruchi, Shrama, Vibandha*, and *Shiroshula* were found in 54.28%, 74.28%, 54.28%, and 45.71% patients, respectively. These are symptoms of *Vata* vitiation and are again indicative of the relationship of *Kashtartava* with *Vata*.

![Associated symptoms in patients](Ayu-31-305-g005){#F4}

Effect of therapy {#sec2-11}
-----------------

The effect of therapy on severity and duration of pain is shown in [Figure 5](#F5){ref-type="fig"}. Encouraging results were found in the associated features of disease also, with improvement in the symptoms of *Vibandha, Vankshana Kati Janu Shula, and Shrama*, as well as improvement in *Alpartava* \[[Figure 6](#F6){ref-type="fig"}\]. The overall results in both the groups are equivalent, as 38.89% in group A and 35.39% in group B had complete remission. In the same way, 11.11% and 50% in group A and 17.64% and 47.65% patients in group B had marked improvement and mild improvement, respectively \[[Figure 7](#F7){ref-type="fig"}\]. It denotes that this therapy is effective for relief of pain as well as of the associated symptoms. Thus, the results suggest that *Matra Basti* can be established as an effective treatment for most of the complaints related to *Kashtartava*. It supports to fulfill the main objective of the study.

![Effect of therapy on cardinal symptoms](Ayu-31-305-g006){#F5}

![Effect of therapy on associated symptoms](Ayu-31-305-g007){#F6}
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Probable mode of action of *Dashamoola Taila* {#sec2-12}
---------------------------------------------

According to the concept of *Viryasamkranti* (transformation of potency) described by Acharya Charaka,\[[@ref12]\] the potency of *Dashamoola* is already transferred in *Dashamoola Kwatha*, and the potency of *Dashamoola* in the *Kalka* form, on processing with oil, further causes the *Viryasamkranti* into the *Taila*. Thus the *Taila* carries the whole potency of the drug in it. *Madhura, Tikta, Kashaya Rasa, Guru, Snighda Guna, Ushna Veerya, Madhura Katu, Vipaka, and Tridoshanashaka Karma* of *Dashamoola Taila* acts on *Kashtartava* by its *Dravya, Guna*, and *Prabhava*. It has being proven that *Dashamoola* has anti-inflammatory, analgesic, and antipyretic\[[@ref13]\] actions.

Probable mode of action of *Tila Taila* {#sec2-13}
---------------------------------------

*Tila Taila* is of *Madhura Rasa* and *Vipaka, Balya*, and *Rasayana* in *Karma*; it nourishes and strengthens all the *Dhatus*, checks *Dhatukshaya*, and thus alleviates *Vata. Snigdha* and *Guru Guna* decreases *Rukshata* of *Vata*\[[@ref14]\] and with the help of *Ushna, Guna*, and *Veerya* it alleviates *Vata*; the *Vikasi* property reduces the spasms. *Sukskshmata* dilates the channels and *Vishada* prevents stickiness of the channels and thus helps in normal flow of menstrual blood. *Garbhashaya Shodhana, Artavajanana* properties\[[@ref8]\] of *Tila Taila* indicates its specific action on genital tract and regulates function of *Apana Vayu* on particular system. Especially when administered in the form of *Basti, Tila Taila* directly works on *Apana Vata*, and by its *Yonishula Nashana* action it works upon *Kashtartava*. Sesame oil (*Tila Taila*) is a good source of vitamin E (1.4 mg/100 g)\[[@ref15]\] and it also contains magnesium, copper, calcium, iron, zinc, and vitamin B~6~, all of which have being reported as having beneficial effects in dysmenorrhea\[[@ref16]\] by several pharmacological and clinical trials.

In this study *Snehana* and *Swedana* also influence the results. *Matra Basti* on *Kashtartava* deals mainly with the *Apana Vayu* as the organs situated nearby are its seat. *Snehana* and *Svedana* prior to *Matra Basti* does its *Anulomana* and thus *Matra Basti* becomes more efficacious. Modern science too has recognized that local heat has a good effect on primary dysmenorrhea.\[[@ref17]\]

Follow-up {#sec2-14}
---------

During the follow-up period we found a marked difference between the groups. Most of the patients, who were treated with the *Tila Taila* returned with the same complaint. This suggests that the effect of *Dashamoola* lasts longer than that of *Tila Taila*. The difference between the groups with regard to recurrence of symptoms could be due to the strong anti-inflammatory and analgesic properties of *Dashamoola*. It is a proven drug, effective in primary neurological disorders and is known to improve nerve conduction velocity.\[[@ref18]\] This effect of *Dashamoola* on the nervous system may be the factor responsible for its lasting effect.

Conclusion {#sec1-6}
==========

*Kashtartava* can be co-related with all the types of dysmenorrhea but when it is due to only *Vata*, it has the same features as primary dysmenorrhea. *Matra Basti* is found to be efficacious in the whole symptom complex of Kashtartava. *Tila Taila Matra Basti* and *Dashamoola Taila Matra Basti* are both highly effective in *Kashtartava. Dashamoola Taila Matra Basti* also helps to prevent recurrence of dysmenorrhea. With further research, *Matra Basti* can be established as the preferred line of treatment in *Kashtartava*.
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